Holen Sie sich die Stockscreener-App
56.37
5.74%
3.06
Handel nachbörslich:
55.41
-0.96
-1.70%
Schlusskurs vom Vortag:
$53.31
Offen:
$55
24-Stunden-Volumen:
1.93M
Relative Volume:
3.30
Marktkapitalisierung:
$2.79B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-105.43M
KGV:
-24.32
EPS:
-2.3183
Netto-Cashflow:
$-88.42M
1W Leistung:
+23.84%
1M Leistung:
+70.97%
6M Leistung:
+177.27%
1J Leistung:
+619.92%
1-Tages-Spanne:
$54.76
$58.99
1-Wochen-Bereich:
$46.07
$58.99
52-Wochen-Spanne:
$5.485
$58.99
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Firmenname
Oruka Therapeutics Inc
Sektor
Branche
Telefon
650-606-7910
Adresse
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
56.37 | 2.64B | 0 | -105.43M | -88.42M | -2.3183 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-13 | Eingeleitet | Jefferies | Buy |
| 2025-10-27 | Eingeleitet | Guggenheim | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-11 | Eingeleitet | Stifel | Buy |
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | Leerink Partners | Outperform |
| 2024-09-16 | Eingeleitet | TD Cowen | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-02-27 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Eingeleitet | Dawson James | Buy |
Alle ansehen
Oruka Therapeutics Inc Aktie (ORKA) Neueste Nachrichten
Oruka Therapeutics (NASDAQ:ORKA) Hits New 52-Week HighHere's Why - MarketBeat
Secure Asset Management LLC Takes Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Does Oruka Therapeutics' (ORKA) $1 Billion Shelf Plan Reframe Its Long-Term Capital Strategy? - simplywall.st
ORKA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oruka Therapeutics may offer up to $1 billion of securities from time to timeSEC filing - marketscreener.com
Oruka Therapeutics May Offer Up To $1 Billion Of Securities From Time To TimeSEC Filing - TradingView
Oruka Therapeutics (NASDAQ: ORKA) files $1B shelf to sell equity, warrants - Stock Titan
Oruka Therapeutics stock hits 52-week high at 50.11 USD By Investing.com - au.investing.com
HC Wainwright & Co. Maintains Oruka Therapeutics (ORKA) Buy Recommendation - MSN
ORKA-001 Phase 1 Completion: What Oruka’s First-in-Human Milestone Means for Investors - TipRanks
Oruka Therapeutics stock hits 52-week high at 50.11 USD - investing.com
Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month HighShould You Buy? - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Down 18.4% in March - MarketBeat
How does Oruka Therapeutics Inc compare to its peersProfit Target & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Oruka Therapeutics and Clearmind Medicine Vie for Investor Dollars - National Today
Vanguard realignment leaves Oruka Therapeutics (ORKA) holdings at 0 after disaggregation - Stock Titan
458,946 Shares in Oruka Therapeutics, Inc. $ORKA Acquired by Synergy Asset Management LLC - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 5.6%Here's Why - MarketBeat
Oruka Therapeutics stock hits 52-week high at 43.0 USD By Investing.com - au.investing.com
Momentum Shift: Will Oruka Therapeutics Inc benefit from AI trendsQuarterly Profit Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Oruka Therapeutics (NASDAQ:ORKA) Hits New 12-Month HighShould You Buy? - MarketBeat
Oruka Therapeutics stock hits 52-week high at 43.0 USD - Investing.com
Aug Selloffs: Will Oruka Therapeutics Inc outperform tech stocksQuarterly Investment Review & AI Powered Market Entry Strategies - baoquankhu1.vn
Does Oruka’s Widening Loss and ESOP Shelf Registration Change The Bull Case For Oruka Therapeutics (ORKA)? - Yahoo Finance
Piper Sandler reiterates Oruka Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
Piper Sandler reiterates Oruka Therapeutics stock rating at Overweight - Investing.com
Oruka Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | | US6876041087 - marketscreener.com
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Oruka Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | HQ1 | US6876041087 - marketscreener.com
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week HighStill a Buy? - MarketBeat
Does Oruka Therapeutics, Inc. (ORKA) have the potential to rally 41.51% as Wall Street analysts expect? - MSN
Oruka Therapeutics (ORKA) chief medical officer sells $313k in stock - Investing.com India
BTIG Reiterates Oruka Therapeutics (ORKA) Buy Recommendation - msn.com
Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $16,313.50 in Stock - MarketBeat
Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells 7,641 Shares of Stock - MarketBeat
Oruka Therapeutics (ORKA) chief medical officer sells $313k in stock By Investing.com - za.investing.com
Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $71,407.70 in Stock - MarketBeat
Agarwal Arjun, Oruka Therapeutics SVP, sells $16k in ORKA stock - Investing.com Canada
[Form 4] Oruka Therapeutics, Inc. Insider Trading Activity - Stock Titan
Does Oruka Therapeutics, Inc. (ORKA) Have a Chance to Surge 41.51% According to Wall Street Analysts’ Predictions? - Bitget
Does Oruka Therapeutics, Inc. (ORKA) Have the Potential to Rally 41.51% as Wall Street Analysts Expect? - Yahoo Finance
Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $86.00 at Leerink Partners - Defense World
Is Oruka Therapeutics’ (ORKA) ESOP Shelf Registration Quietly Redefining Its Funding Playbook? - simplywall.st
Oruka Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Oruka Therapeutics, Inc. $ORKA is Fairmount Funds Management LLC's 7th Largest Position - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Raised to Hold at Wall Street Zen - MarketBeat
Commodore Capital LP Has $33.71 Million Stake in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Braidwell LP Sells 142,492 Shares of Oruka Therapeutics, Inc. $ORKA - MarketBeat
BTIG Research Reaffirms “Buy” Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Wedbush Reaffirms Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Finanzdaten der Oruka Therapeutics Inc-Aktie (ORKA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oruka Therapeutics Inc-Aktie (ORKA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Agarwal Arjun | Senior Vice President, Finance |
Mar 16 '26 |
Sale |
41.30 |
395 |
16,313 |
18,863 |
| Sandler Laura Lee | Chief Operating Officer |
Mar 16 '26 |
Sale |
41.30 |
600 |
24,780 |
236,984 |
| Goncalves Joana | Chief Medical Officer |
Mar 16 '26 |
Option Exercise |
7.32 |
7,000 |
51,240 |
41,018 |
| Goncalves Joana | Chief Medical Officer |
Mar 16 '26 |
Sale |
40.91 |
7,641 |
312,560 |
33,377 |
| Quinlan Paul T | General Counsel |
Mar 16 '26 |
Sale |
41.30 |
733 |
30,273 |
31,767 |
| Sandler Laura Lee | Chief Operating Officer |
Mar 02 '26 |
Option Exercise |
7.80 |
5,000 |
39,000 |
242,584 |
| Sandler Laura Lee | Chief Operating Officer |
Mar 02 '26 |
Sale |
33.56 |
5,000 |
167,822 |
237,584 |
| Goncalves Joana | Chief Medical Officer |
Feb 17 '26 |
Option Exercise |
7.32 |
7,000 |
51,240 |
41,018 |
| Goncalves Joana | Chief Medical Officer |
Feb 17 '26 |
Sale |
32.37 |
7,000 |
226,559 |
34,018 |
| Goncalves Joana | Chief Medical Officer |
Jan 15 '26 |
Option Exercise |
7.32 |
7,000 |
51,240 |
8,518 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):